At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
SLNO Soleno Therapeutics
Closed 01-12 16:00:00 EST
41.54
-1.46
-3.40%
盘后41.41
-0.13-0.31%
18:30 EST
High45.46Low40.00Vol3.49M
Open45.46D1 Closing43.00Amplitude12.69%
Mkt Cap2.23BTradable Cap1.86BTotal Shares53.71M
T/O147.29MT/O Rate7.79%Tradable Shares44.87M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Soleno Therapeutics price target lowered to $60 from $75 at Wolfe Research
TIPRANKS  ·  02:55
Soleno Therapeutics price target lowered to $60 from $75 at Wolfe Research
BUZZ-U.S. STOCKS ON THE MOVE-AbCellera Biologics, Zymeworks, Silver miners
Reuters  ·  01-12 23:40
BUZZ-U.S. STOCKS ON THE MOVE-AbCellera Biologics, Zymeworks, Silver miners
Soleno Therapeutics Reverse Premarket Gains, Last Down 1.7%
THOMSON REUTERS  ·  01-12 22:36
Soleno Therapeutics Reverse Premarket Gains, Last Down 1.7%
Soleno Therapeutics Preliminary Q4 Net Revenue Beats Analyst Estimates
MT Newswires Live  ·  01-12 21:09
Soleno Therapeutics Preliminary Q4 Net Revenue Beats Analyst Estimates
Soleno Therapeutics Projects 2025 Net Revenue of Up to $191 Million
Reuters  ·  01-12 20:03
Soleno Therapeutics Projects 2025 Net Revenue of Up to $191 Million
Soleno Therapeutics Inc Q4 REV View $81.7 Mln -- Lseg Ibes Data
THOMSON REUTERS  ·  01-12 20:00
Soleno Therapeutics Inc Q4 REV View $81.7 Mln -- Lseg Ibes Data
Soleno Therapeutics Announces Select Preliminary Fourth Quarter and Full-Year 2025 Results
THOMSON REUTERS  ·  01-12 20:00
Soleno Therapeutics Announces Select Preliminary Fourth Quarter and Full-Year 2025 Results
Soleno Therapeutics Inc - 2025 Net Revenue From US Sales of Vykat Xr Since Q2 Expected Between $189 Mln-$191 Mln
THOMSON REUTERS  ·  01-12 20:00
Soleno Therapeutics Inc - 2025 Net Revenue From US Sales of Vykat Xr Since Q2 Expected Between $189 Mln-$191 Mln
Soleno Therapeutics Inc - Achieves Profitability and Positive Cash Flow
THOMSON REUTERS  ·  01-12 20:00
Soleno Therapeutics Inc - Achieves Profitability and Positive Cash Flow
Soleno Therapeutics Inc - Vykat Xr Discontinuation Rate Due to Adverse Events About 12%, as of Q4 End
THOMSON REUTERS  ·  01-12 20:00
Soleno Therapeutics Inc - Vykat Xr Discontinuation Rate Due to Adverse Events About 12%, as of Q4 End
Will Peer‑Reviewed VYKAT XR Data Calm Safety Debate And Change Soleno Therapeutics' (SLNO) Narrative?
Simply Wall St.  ·  01-09
Will Peer‑Reviewed VYKAT XR Data Calm Safety Debate And Change Soleno Therapeutics' (SLNO) Narrative?
Soleno Therapeutics Reports Positive Phase 3 Results for VYKAT XR in Prader-Willi Syndrome
Reuters  ·  01-05
Soleno Therapeutics Reports Positive Phase 3 Results for VYKAT XR in Prader-Willi Syndrome
BUZZ-Oppenheimer starts Aardvark with 'outperform' on differentiated obesity franchise
Reuters  ·  2025-12-23
BUZZ-Oppenheimer starts Aardvark with 'outperform' on differentiated obesity franchise
Soleno Therapeutics (SLNO) Valuation Check After Wolfe’s Bullish Call Challenges Short-Seller Concerns
Simply Wall St.  ·  2025-12-04
Soleno Therapeutics (SLNO) Valuation Check After Wolfe’s Bullish Call Challenges Short-Seller Concerns
Press Release: Soleno Therapeutics Announces the Passing of Board Member William G. Harris
Dow Jones  ·  2025-12-04
Press Release: Soleno Therapeutics Announces the Passing of Board Member William G. Harris
How Does Wolfe Research’s Support Shape Soleno Therapeutics’ (SLNO) Credibility Amid Heightened Scrutiny?
Simply Wall St.  ·  2025-12-02
How Does Wolfe Research’s Support Shape Soleno Therapeutics’ (SLNO) Credibility Amid Heightened Scrutiny?
Soleno Therapeutics Files Initial Beneficial Ownership Statement for Chief Business Officer Kevin Norrett
Reuters  ·  2025-11-20
Soleno Therapeutics Files Initial Beneficial Ownership Statement for Chief Business Officer Kevin Norrett
Soleno Therapeutics Announces Entry Into $100 Million Accelerated Share Repurchase Agreement
Reuters  ·  2025-11-20
Soleno Therapeutics Announces Entry Into $100 Million Accelerated Share Repurchase Agreement
Soleno Therapeutics Initiated at Outperform by Wolfe Research
Dow Jones  ·  2025-11-19
Soleno Therapeutics Initiated at Outperform by Wolfe Research
Soleno Therapeutics Unveils Corporate Presentation Highlighting VYKAT XR Launch for Prader-Willi Syndrome Hyperphagia
Reuters  ·  2025-11-19
Soleno Therapeutics Unveils Corporate Presentation Highlighting VYKAT XR Launch for Prader-Willi Syndrome Hyperphagia

Introduction

Company Name.
Soleno Therapeutics
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California.
Issue price:
--